Bausch Health Companies Yönetim

Yönetim kriter kontrolleri 2/4

Bausch Health Companies CEO'su Tom Appio, May2022 tarihinde atandı, in görev süresi 2.5 yıldır. in toplam yıllık tazminatı $ 15.88M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.4% maaş ve 92.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.12% ine doğrudan sahiptir ve bu hisseler € 3.35M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.5 yıl ve 8.3 yıldır.

Anahtar bilgiler

Tom Appio

İcra Kurulu Başkanı

US$15.9m

Toplam tazminat

CEO maaş yüzdesi	7.4%
CEO görev süresi	2.5yrs
CEO sahipliği	0.1%
Yönetim ortalama görev süresi	2.5yrs
Yönetim Kurulu ortalama görev süresi	8.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Tom Appio'un ücretlendirmesi Bausch Health Companies'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$178m
Jun 30 2024	n/a	n/a	-US$471m
Mar 31 2024	n/a	n/a	-US$455m
Dec 31 2023	US$16m	US$1m	-US$592m
Sep 30 2023	n/a	n/a	-US$963m
Jun 30 2023	n/a	n/a	-US$186m
Mar 31 2023	n/a	n/a	-US$357m
Dec 31 2022	US$13m	US$1m	-US$225m
Sep 30 2022	n/a	n/a	US$254m
Jun 30 2022	n/a	n/a	US$43m
Mar 31 2022	n/a	n/a	-US$407m
Dec 31 2021	US$10m	US$854k	-US$948m
Sep 30 2021	n/a	n/a	-US$1b
Jun 30 2021	n/a	n/a	-US$1b
Mar 31 2021	n/a	n/a	-US$1b
Dec 31 2020	US$4m	US$775k	-US$560m
Sep 30 2020	n/a	n/a	-US$2b
Jun 30 2020	n/a	n/a	-US$2b
Mar 31 2020	n/a	n/a	-US$2b
Dec 31 2019	US$4m	US$769k	-US$2b
Sep 30 2019	n/a	n/a	-US$616m
Jun 30 2019	n/a	n/a	-US$917m
Mar 31 2019	n/a	n/a	-US$2b
Dec 31 2018	US$4m	US$730k	-US$4b
Sep 30 2018	n/a	n/a	-US$3b
Jun 30 2018	n/a	n/a	-US$2b
Mar 31 2018	n/a	n/a	-US$805m
Dec 31 2017	US$3m	US$650k	US$2b

Tazminat ve Piyasa: Tom 'nin toplam tazminatı ($USD 15.88M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.93M ).

Tazminat ve Kazançlar: Tom şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Tom Appio (62 yo)

2.5yrs

Görev süresi

US$15,878,578

Tazminat

Mr. Thomas J. Appio, also known as Tom, serves as the Chief Executive Officer & Director at Bausch Health Companies Inc. and served as Chief Executive Officer of Pharma Business and served as President & C...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Thomas Appio	CEO & Director	2.5yrs	US$15.88m	0.12% € 3.3m
Seana Carson	Executive VP & General Counsel	2.5yrs	US$3.16m	0.035% € 986.5k
Jean-Jacques Charhon	Executive VP & CFO	less than a year	Veri yok	Veri yok
Mirza Dautbegovic	Executive VP & COO	2.8yrs	Veri yok	0.035% € 998.7k
Garen Sarafian	VP & Head of Investor Relations	no data	Veri yok	Veri yok
Kathleen Fitzpatrick	Executive VP and Chief HR & Communications Officer	2.8yrs	Veri yok	Veri yok
Cees Heiman	Senior Vice President of Europe & Canada	2.8yrs	Veri yok	Veri yok
Donald Pearl	Senior Vice President of Ortho Dermatologics	no data	Veri yok	Veri yok
Jiny Kim	Senior Vice President of Solta Medical	1.8yrs	Veri yok	Veri yok
Aimee Lenar	Executive Vice President of US Pharma	less than a year	Veri yok	Veri yok
William Woodfield	Senior VP & Treasurer	no data	Veri yok	Veri yok

2.5yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: BVF 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Thomas Appio	CEO & Director	2.5yrs	US$15.88m	0.12% € 3.3m
John Paulson	Independent Chairman	2.4yrs	US$812.50k	0.000060% € 1.7k
Robert Power	Independent Director	16.3yrs	US$389.55k	0.0018% € 50.6k
H. Fibiger	Chairman of External Advisory Board	no data	US$2.00m	Veri yok
Sarah Kavanagh	Independent Director	8.3yrs	US$718.28k	0% € 0
Robert Lenox	Member of the External Advisory Board	15.7yrs	Veri yok	Veri yok
Kathleen Clarence-Smith	Member of the External Advisory Board	15.7yrs	Veri yok	Veri yok
Karoly Nikolich	Member of the External Advisory Board	15.7yrs	Veri yok	Veri yok
Brett Icahn	Independent Director	3.7yrs	US$691.72k	0.00020% € 5.7k
Amy Wechsler	Independent Director	8.4yrs	US$377.50k	0.011% € 323.9k
Steven Miller	Independent Director	3.7yrs	US$381.31k	0.031% € 867.5k
Christian Garcia	Independent Director	less than a year	Veri yok	Veri yok

8.3yrs

Ortalama Görev Süresi

67yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: BVF 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.3 yıldır).

Bausch Health Companies Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Bausch Health Companies Inc. Announces Appointment of Aimee Lenar as Executive Vice President, US Pharma

Bausch Health Companies Inc. Approves Directorate Appointments

Insufficient new directors

Bausch Health Companies Inc., Annual General Meeting, May 14, 2024

Bausch Health Companies Inc. Announces Executive Changes

Insider recently sold €708k worth of stock

Recent updates

Bausch Health Companies Inc. Receives Positive Reimbursement Recommendations for Cabtreo in Canada

Third quarter 2024 earnings released: US$0.23 loss per share (vs US$1.03 loss in 3Q 2023)

Forecast breakeven date moved forward to 2024

Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Results of an Analysis of Xifaxan (rifaximin) Monotherapy Will Be Presented During A Presidential Plenary Session of the American College of Gastroenterology 2024 Annual Scientific Meeting Taking Place October 25-30 in Philadelphia, PA

Bausch Health Companies Inc. to Report Q3, 2024 Results on Oct 30, 2024

Health Canada Approves the Bausch Health's (Pr)CABTREO Topical Gel

Second quarter 2024 earnings released: EPS: US$0.027 (vs US$0.071 in 2Q 2023)

Bausch Health Companies Inc. Raises Earnings Guidance for the Full Year 2024

Bausch Health Companies Inc. Announces Appointment of Aimee Lenar as Executive Vice President, US Pharma

Bausch Health Companies Inc. to Report Q2, 2024 Results on Aug 01, 2024

Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

Bausch Health Companies Inc. Approves Directorate Appointments

First quarter 2024 earnings released: US$0.17 loss per share (vs US$0.55 loss in 1Q 2023)

Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

Bausch Health Companies Inc. to Report Q1, 2024 Results on May 02, 2024

Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults

Insufficient new directors

Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma

Full year 2023 earnings released: US$1.62 loss per share (vs US$0.62 loss in FY 2022)

Bausch Health Companies Inc., Annual General Meeting, May 14, 2024

Bausch Health Companies Inc. to Report Q4, 2023 Results on Feb 22, 2024

Bausch Health Companies Inc. Announces the U.S. Launch of CABTREO Topical Gel

Bausch Health Companies Inc. and Salix Pharmaceuticals Ltd. Provides Update on Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute

Bausch Health Companies Inc. Announces Positive Topline Results from Global Phase 2 Study Evaluating Amiselimod (An S1p Antagonist) to Treat Ulcerative Colitis

No longer forecast to breakeven

Bausch Health, Canada Announces DUOBRII Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec's Public Drug Plan

No longer forecast to breakeven

Third quarter 2023 earnings released: US$1.04 loss per share (vs US$1.10 profit in 3Q 2022)

FDA Approves Bausch Health Companies Inc. and Its Dermatology Business, Ortho Dermatologics's Cabtreo Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older

Bausch Health Companies Inc. to Report Q3, 2023 Results on Nov 02, 2023

Bausch Health Companies Inc. Announces Executive Changes

Bausch Health Companies Inc. Announces New Treatment PrUCERIS (Budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc

Bausch Health Companies Inc. Raises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$0.072 (vs US$0.40 loss in 2Q 2022)

Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Purchasers of Bausch Health Companies Inc

Bausch Health Companies Inc. to Report Q2, 2023 Results on Aug 03, 2023

New major risk - Financial position

No longer forecast to breakeven

Forecast to breakeven in 2025

First quarter 2023 earnings released: US$0.56 loss per share (vs US$0.19 loss in 1Q 2022)

Bausch Health Companies Inc. Provides Consolidated Earnings Guidance for the Full Year 2023

Forecast breakeven date pushed back to 2025

Full year 2022 earnings released: US$0.62 loss per share (vs US$2.64 loss in FY 2021)

Investor sentiment improves as stock rises 23%

Bausch Health Companies Inc. to Report Q4, 2022 Results on Feb 23, 2023

Investor sentiment improved over the past week

Bausch Health Companies Inc. Announces Availability of ARAZLOTM

Third quarter 2022 earnings released: EPS: US$1.10 (vs US$0.52 in 3Q 2021)

Bausch Health Companies Inc. Revises Consolidated Earnings Guidance for the Full Year 2022

Bausch Health Companies Inc. to Report Q3, 2022 Results on Nov 03, 2022

Bausch Health Companies Inc. and Glenmark Specialty S.A. Announce the Approval of RYALTRIS® in Canada

Insider recently sold €708k worth of stock

Bausch Health Companies Inc.(TSX:BHC) dropped from FTSE All-World Index (USD)

Investor sentiment improved over the past week

Bausch Health Companies Inc. Responds to Norwich Pharmaceuticals Tentative FDA Approval for 200 mg Rifaximin

Investor sentiment improved over the past week

Bausch Health Companies Inc. to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit

Second quarter 2022 earnings released

Bausch Health Companies Inc. Announces Unaudited Impairment Results for the Quarter Ended June 30, 2022

Insufficient new directors

Bausch Health Companies Inc. to Report Q2, 2022 Results on Aug 09, 2022

Insufficient new directors

Bausch Health Companies Inc. Announces Updates to Its Board of Directors

Bausch Health Companies Inc. Appoints John S. Barresi as the Company’s Senior Vice President, Controller and Chief Accounting Officer

Bausch Health Companies Inc. Provides Revenue Guidance for the Year Full Year 2022

Bausch Health Companies Inc. Announces Management Changes

Bausch Health Companies Inc. to Report Q1, 2022 Results on May 10, 2022